Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT04958382
Other study ID # HSK3486-IIT-01
Secondary ID
Status Active, not recruiting
Phase N/A
First received
Last updated
Start date December 1, 2021
Est. completion date June 1, 2024

Study information

Verified date November 2023
Source Sichuan Provincial People's Hospital
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This is a single center, randomized, single blind, exploratory clinical study.About 30 patients with chronic insomnia are planned to be enrolled in this study and randomized into two groups by a ratio of 4:1 (Figure 1), with group 1 (24 subjects) for ciprofol and group 2 (6 subjects) for placebo (fat emulsion). Cognitive behavioral therapy (CBT) will be given to these patients during the treatment.


Recruitment information / eligibility

Status Active, not recruiting
Enrollment 30
Est. completion date June 1, 2024
Est. primary completion date December 31, 2023
Accepts healthy volunteers No
Gender All
Age group 18 Years to 70 Years
Eligibility Inclusion Criteria: 1. Male or female aged 18 (inclusive) to 70 (inclusive) years old; 2. ASA class of I-II; 3. With chronic insomnia refractory to conventional drugs in the past 3 months (benzodiazepine receptor agonists and other drugs). Other drugs: melatonin, melatonin receptor agonists, and traditional Chinese medicine; 4. Compliant with the diagnostic criteria of ICSD-3 chronic insomnia: 1. At least one of the following chief complaints: initial insomnia, difficulty in sleep maintenance, early awakening, refusal to go to bed at an appropriate time, and difficulty in falling asleep without nursing; 2. At least one of the following daytime symptoms: tiredness, short tempered, work/study/social skills decreased; 3. Occurrence of the above symptoms at least 3 times per week and lasting for more than 3 months; 5. Voluntarily adopt narcotic sleep and obtain the written informed consent form. Exclusion Criteria: 1. With contraindications to deep sedation/general anesthesia or a history of past sedation/anesthesia accidents; 2. With a history of allergy or contraindications to anesthetics; 3. With a medical history or evidence of any of the followings before screening/at baseline, which may increase sedation/anesthesia risks: 1. History of cardiovascular diseases: uncontrolled hypertension [systolic blood pressure (SBP) = 170 mmHg and/or diastolic blood pressure (DBP) = 105 mmHg without treatment, or SBP > 160 mmHg and/or DBP > 100 mmHg despite antihypertensive treatment], severe arrhythmia, heart failure, Adams-stokes syndrome, New York Heart Association (NYHA) Class = III, severe superior vena cava syndrome, pericardial effusion, acute myocardial ischemia, unstable angina, myocardial infarction within 6 months before screening, history of tachycardia/bradycardia requiring medical treatment, II-III degree atrioventricular block (excluding patients with pacemakers); 2. History of respiratory system disorders: respiratory insufficiency, history of obstructive pulmonary disease, history of bronchospasm requiring treatment within 3 months before screening, and acute respiratory tract infection with obvious symptoms such as fever, wheezing, nasal obstruction, and cough within 1 week before baseline; 3. History of neurological and psychiatric disorders: craniocerebral injury, possible convulsions, myoclonus, intracranial hypertension, cerebral aneurysms, history of cerebrovascular accidents; schizophrenia, mania, insanity, history of cognitive disorder; history of epilepsy; mental disorder suggested by Mini International Neuropsychiatric Interview (MINI); 4. History of gastrointestinal disorders: gastrointestinal retention, active hemorrhage, or conditions that may lead to reflux and aspiration; 5. History of blood donation or blood loss of = 400 mL within 3 months before screening; 4. With the following airway management risks at screening: 1. History of asthma or stridor; 2. Sleep apnea syndrome; 3. History or family history of malignant hyperthermia; 4. History of tracheal intubation failure; 5. Judged by investigators to have difficult airway or judged as difficult tracheal intubation (modified Mallampati class IV) at screening; 5. Receipt of any of the following medications/therapies at screening/baseline: 1. Any clinical study within 1 month before screening; 2. Sedatives/anesthetics, and/or sedative-hypnotics within 72 h before baseline; 3. Antidepressants and anxiolytics within 14 days before baseline; 6. Laboratory test abnormalities at screening: 1. Total bilirubin > 2 × ULN (upper limit of normal); 2. Aspartate aminotransferase (AST) and alanine transaminase (ALT) > 2 × ULN; 3. Blood creatinine > 1.5 × ULN; 7. Unable to fast for 6 h before dose administration; 8. With a history of smoking, drug abuse and/or positive urine drug screening results, or positive breath alcohol test results at baseline and/or a history of alcohol abuse within 3 months before screening. Alcohol abuse is defined as an average of > 2 units of alcohol consumed per day (1 unit = 360 mL of beer with 5% alcohol, 45 mL of liquor with 40% alcohol, or 150 mL of wine); 9. Pregnant or breastfeeding females; women of child-bearing potential or men who are unwilling to use contraception during the trial; or patients who are planning pregnancy within 1 month after the trial (including male patients); 10. Unable to avoid engaging in dangerous occupations requiring concentration and/or motor coordination 72 h after administration; 11. Judged by investigators to be unsuitable for participating in this trial for any reason.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
ciprofol
intravenous infusion of ciprofol at 0.12 mg/kg, followed by 0.4-1.6 mg/kg/h for maintenance
medium/long chain fat emulsion injection (C8-24Ve)
at the infusion rate of 25-30 mL/h

Locations

Country Name City State
China Sichuan Provincial People's Hospital Sichuan

Sponsors (1)

Lead Sponsor Collaborator
Sichuan Provincial People's Hospital

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary Polysomnography (PSG) total sleep time (TST) Day -2 to Day 90
Primary Polysomnography (PSG) sleep latency (SL) Day -2 to Day 90
Primary Polysomnography (PSG) wake after sleep onset (WASO) Day -2 to Day 90
Primary Sleep log subjective total sleep time (sTST) Day -2 to Day 90
Primary Sleep log subjective sleep-onset latency (sSOL) Day -2 to Day 90
Primary Sleep log subjective wake after sleep onset (sWASO) Day -2 to Day 90
Secondary Self-rating scales Pittsburgh Sleep Quality Index (PSQI)(0-21) Day -2 to Day 90
Secondary Self-rating scales Insomnia Severity Index (ISI)(0-28) Day -2 to Day 90
Secondary Self-rating scales PHQ-9 Depression Test Questionnaire(0-27) Day -2 to Day 90
Secondary Self-rating scales GAD-7 Anxiety Test Questionnaire(0-21) Day -2 to Day 90
Secondary Self-rating scales Epworth Somnolence Scale(0-24); Day -2 to Day 90
See also
  Status Clinical Trial Phase
Completed NCT03171519 - Effects of Exercise and Acupuncture on Chronic Insomnia N/A
Completed NCT02515006 - Impact of Homeopathy for Persistent Insomnia in Patients With Cancer N/A
Recruiting NCT05247697 - Mirtazapine for Chronic Insomnia in Older Adults Phase 1
Active, not recruiting NCT04366284 - Optimizing the Scalability of Evidence-Based Behavioral Sleep Medicine Practices With a Digital Health Platform N/A
Active, not recruiting NCT04350866 - Enhancing Access to Insomnia Care in VA PCMHI Clinics
Recruiting NCT04761796 - Sleep Time and Insomnia Factors Among Professional Flight Members
Completed NCT02688569 - Sleep and Pain Intervention for Chronic Widespread Pain Pilot Study N/A
Completed NCT02236845 - Pilot Study to Clinical Evaluate Lacrima Medical Device in Insomnia Patients N/A
Completed NCT01949389 - Piloting an Internet-based Therapy for Insomnia in a Population of Veterans With Substance Use Disorders N/A
Completed NCT00414102 - Subjective Efficacy of Ramelteon on Sleep in Adults With Chronic Insomnia. Phase 4
Completed NCT00671294 - Safety and Efficacy of Ramelteon in Elderly Subjects With Chronic Insomnia. Phase 3
Completed NCT02392000 - Mobile Sleep Intervention for OEF, OIF and OND Veterans N/A
Recruiting NCT04471168 - Interest of Auriculotherapy in the Management of Chronic Insomnia N/A
Completed NCT02774642 - Integrated CBT-I and PE on Sleep and PTSD Outcomes (Impact Study) N/A
Completed NCT02290405 - Impact of Hyperarousal on Simple and Complex Cognitive Task Performance Among Insomnia Sufferers
Completed NCT05618002 - Lemborexant vs Zopiclone vs Clonidine for Insomnia Treatment in Chronic Pain Patients
Completed NCT01995838 - A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Bayesian Adaptive Randomization Design, Dose Response Study of the Efficacy of E2006 in Adults and Elderly Subjects With Chronic Insomnia Phase 2
Recruiting NCT05457790 - Feasibility and Preliminary Efficacy of Acceptance and Commitment Therapy (ACT) for Sleep Disturbances in Adults With Sickle Cell Disease (SCD) N/A
Completed NCT02272712 - The Effectiveness of Online Treatment for Insomnia in Cancer Survivors N/A
Completed NCT00915135 - Efficacy and Safety of Ramelteon on Chronic Insomnia Phase 2